Investor Relations

Aduro is a clinical-stage cancer immunotherapy company with three products currently in human trials. The company’s lead candidate – an immunotherapy regimen combining our proprietary CRS-207 with GVAX Pancreas – is targeting metastatic pancreatic cancer and has received Breakthrough Therapy designation from the US Food and Drug Administration.
NASDAQ ADRO (Common Stock) $11.29Stock is Down0.211.83%)December 08, 201612:39 p.m. ET

Stock Chart

Stock chart for: ADRO.O.  Currently trading at $11.29 with a 52 week high of $34.95 and a 52 week low of $7.26.
Data Provided by Thomson Reuters